381 related articles for article (PubMed ID: 28760226)
41. Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE.
Cornell S
J Am Pharm Assoc (2003); 2017; 57(2):261-265. PubMed ID: 28065547
[TBL] [Abstract][Full Text] [Related]
42. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
[TBL] [Abstract][Full Text] [Related]
43. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
Choi CI
Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis.
Zhang L; Zhang M; Lv Q; Tong N
Diabetes Res Clin Pract; 2018 Jun; 140():295-303. PubMed ID: 29649541
[TBL] [Abstract][Full Text] [Related]
45. Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats.
Londzin P; Brudnowska A; Kurkowska K; Wilk K; Olszewska K; Ziembiński Ł; Janas A; Cegieła U; Folwarczna J
Biomed Pharmacother; 2022 Nov; 155():113679. PubMed ID: 36099792
[TBL] [Abstract][Full Text] [Related]
46. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
Engelhardt K; Ferguson M; Rosselli JL
Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
[TBL] [Abstract][Full Text] [Related]
47. Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Estrada AK; Delgado-Maldonado T; Lara-Ramírez EE; Martínez-Vázquez AV; Ortiz-Pérez E; Paz-González AD; Bandyopadhyay D; Rivera G
Mini Rev Med Chem; 2022; 22(4):586-599. PubMed ID: 34353256
[TBL] [Abstract][Full Text] [Related]
48. Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus.
Xie T; Zhao LJ
Eur J Med Chem; 2024 Apr; 269():116343. PubMed ID: 38513341
[TBL] [Abstract][Full Text] [Related]
49. Clinical relevance of the selectivity of sodium-glucose cotransporter-2 inhibitors.
Morales-Olivas FJ
Med Clin (Barc); 2016 Nov; 147 Suppl 1():26-29. PubMed ID: 28760222
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis.
El Masri D; Ghosh S; Jaber LA
Diabetes Res Clin Pract; 2018 Mar; 137():83-92. PubMed ID: 29317332
[TBL] [Abstract][Full Text] [Related]
51. [Recommendations of the main clinical practice guidelines].
Miravet I Jiménez S
Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
[TBL] [Abstract][Full Text] [Related]
52. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
[TBL] [Abstract][Full Text] [Related]
53. [Mechanisms and efficacy of SGLT2 inhibitors].
Shiba T
Nihon Rinsho; 2015 Mar; 73(3):438-46. PubMed ID: 25812370
[TBL] [Abstract][Full Text] [Related]
54. The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm.
Rodbard HW; Jellinger PS
Diabetologia; 2010 Nov; 53(11):2458-60. PubMed ID: 20835856
[No Abstract] [Full Text] [Related]
55. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
[TBL] [Abstract][Full Text] [Related]
56. Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Zhang L; Wang Y; Xu H; Shi Y; Liu B; Wei Q; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2014 May; 10(3):304-17. PubMed ID: 24059684
[TBL] [Abstract][Full Text] [Related]
57. Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes.
Sharma S; Mittal A; Kumar S; Mittal A
Curr Diabetes Rev; 2022; 18(6):e170921196601. PubMed ID: 34538233
[TBL] [Abstract][Full Text] [Related]
58. [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
García SD; Sanz SD; Sanz AD
Med Clin (Barc); 2013 Sep; 141 Suppl 2():14-9. PubMed ID: 24444519
[TBL] [Abstract][Full Text] [Related]
59. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
Takeda K; Ono H; Ishikawa K; Ohno T; Kumagai J; Ochiai H; Matumoto A; Yokoh H; Maezawa Y; Yokote K
BMJ Open Diabetes Res Care; 2021 Apr; 9(1):. PubMed ID: 33879516
[TBL] [Abstract][Full Text] [Related]
60. SGLT2 inhibition and glucagon secretion in humans.
Saponaro C; Pattou F; Bonner C
Diabetes Metab; 2018 Nov; 44(5):383-385. PubMed ID: 30017776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
